With ever increasing regulatory requirements in place for healthcare companies and their new products, pharmaceutical organizations must develop innovative risk-mitigation programs to support patients and meet compliance goals.
This critical new Best Practices, LLC study examines how leading organizations build and execute successful Risk Evaluation & Mitigation Strategy (REMS) programs for products in the U.S. marketplace.
This study also provides key insights into how market research groups support high-performing REMS teams, while highlighting collaboration opportunities with Risk Management Plan (RMP) teams working on European products.
Research participants included 22 executives and managers from 19 leading pharmaceutical, biotech, and medical device companies.
All study participants contributed data through a field survey and representatives from several leading benchmark organizations also provided additional insights through deep-dive interviews.